SCHEMBL1573008

SCHEMBL1573008

COc1c(C)c(C(=O)c2ccc3nc(-c4ccccc4)oc(=O)c3c2)n2cc(OCc3ccccc3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAOB P27338 2/20 0.38
▸ ACHE P22303 1/20 0.38
▸ ELANE P08246 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ TP53 P04637 4/20 0.38
▸ HPGD P15428 3/20 0.38
▸ F2 P00734 1/20 0.38
▸ PTPN2 P17706 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572762 0.78 SRD5A2 (0.39) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL320811 0.75 MAPT (0.43) MAPTHSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4509609 0.75 LNPEP (0.42) MAPTHSD17B10ALDH1A1KDM4ELMNA
SCHEMBL320604 0.74 ELANE (0.41) MAPTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL692456 0.70 ELANE (0.62) MAPTHSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3944692 0.68 L3MBTL1 (0.40) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL321784 0.66 ELANE (0.62) MAPTHSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1573145 0.66 RARB (0.34) MAPTHSD17B10ALDH1A1KDM4ERAB9A
SCHEMBL1573232 0.66 ALDH1A1 (0.33) MAPTHSD17B10ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3944817 0.66 MAPT (0.47) MAPTALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 — — EP disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed
EP-2018165-A1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS Sanofi-Aventis (FR) 2009-01-28 — — EP disclosed
WO-2007080325-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 MAPT 3588/4885HSD17B10 2756/4885ALDH1A1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback